Narcolepsy
Overview
Physiology
Authors
Affiliations
Narcolepsy is a neurological condition with a prevalence of up to 1 per 1,000 that is characterized by irresistible bouts of sleep. Associated features include the pathological manifestations of rapid-eye-movement (REM) sleep: cataplexy, sleep paralysis, hypnagogic hallucinations, and abnormal sleep-onset REM periods and disturbed nocturnal sleep. The condition is strongly associated with the HLA-DR2 and DQw1 phenotype. The phenomenology of narcolepsy is discussed, and diagnostic procedures are reviewed. Treatment modalities involving central nervous system stimulants for somnolence and tricyclic drugs for REM-sleep abnormalities are discussed. Sleep laboratory studies on the treatment efficacy of methylphenidate, pemoline, dextroamphetamine, protriptyline, and viloxazine are presented. Data suggest that: (1) methylphenidate and dextroamphetamine objectively improve somnolence; (2) pemoline, at doses up to 112.5 mg, is less effective in controlling somnolence but may improve certain aspects of performance; and (3) protriptyline and viloxazine are effective anticataplectic agents that produce little improvement in somnolence.
Arshad A, Qureshi M, Masood M, Zahoor H, Nazakat A, Fatima A Sleep Med X. 2025; 9():100136.
PMID: 39811427 PMC: 11728066. DOI: 10.1016/j.sleepx.2024.100136.
Recent Insights Into Sleep Paralysis: Mechanisms and Management.
Bhalerao V, Gotarkar S, Vishwakarma D, Kanchan S Cureus. 2024; 16(7):e65413.
PMID: 39184697 PMC: 11344621. DOI: 10.7759/cureus.65413.
Aguilar A, Frange C, Pimentel Filho L, Reis M, Tufik S, Coelho F Braz J Psychiatry. 2019; 42(3):314-316.
PMID: 31859793 PMC: 7236164. DOI: 10.1590/1516-4446-2019-0544.
Treatment of Excessive Daytime Sleepiness in Patients with Narcolepsy.
Perez-Carbonell L Curr Treat Options Neurol. 2019; 21(11):57.
PMID: 31713736 DOI: 10.1007/s11940-019-0595-9.
Sahni A, Carlucci M, Malik M, Prasad B Nat Sci Sleep. 2019; 11:241-252.
PMID: 31695533 PMC: 6815780. DOI: 10.2147/NSS.S218402.